Longeveron Inc (LGVN)

NASDAQHealth CareBiotechnologySnapshot 2026-09-04

$6.81+3.50%

Close 2026-09-04 · 1-day change

QuarterlyIQ Insights · LGVN

Financials

Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.

Income Statement

Period

View

Order

Figures in millions of None, except per-share and ratios.

	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenues
Revenues	1.2	1.2	2.4	0.7	1.2	1.3	5.6
Total Revenues	—	—	—	0.7	1.2	1.3	5.6
Cost of Revenues	0.4	0.4	0.5	0.5	0.7	0.7	3.8
Gross Profit	0.8	0.8	1.9	0.2	0.5	0.6	1.8
Operating Expenses & Income
R&D Expenses	12.1	12.0	8.1	9.1	9.4	7.1	2.7
Operating Income	(23.7)	(23.3)	(16.5)	(21.0)	(18.0)	(17.5)	(3.8)
Earnings from Continuing Operations
Interest Expense	—	—	—	—	1.4	—	—
Other Non-Operating Income / Expenses	0.2	0.6	0.5	(0.4)	(0.8)	—	—
Income Tax Expense	—	0.0	0.0	0.0	0.0	—	—
Earnings from Continuing Operations	—	—	—	—	(18.8)	(17.0)	(3.7)
Net Income
Net Income	(23.5)	(22.7)	(16.0)	(21.4)	(18.8)	(17.0)	(3.7)
Per Share
Basic EPS	(0.75)	(1.29)	(2.62)	(10.22)	(0.90)	(0.90)	—
Diluted EPS	(0.75)	(1.29)	(2.62)	(10.22)	(0.90)	(0.90)	—
Revenue per Share	0.04	—	—	—	—	—	—
Basic Weighted Avg Shares	31.4	17,576.6	9,411.2	2,173.5	21.0	18.9	—
Diluted Weighted Avg Shares	31.4	17,576.6	9,411.2	2,173.5	21.0	18.9	—
Supplemental
EBITDA	—	(22.1)	(15.6)	(20.1)	(17.2)	(17.5)	(3.8)
EBIT	(23.7)	(23.3)	(16.5)	(21.0)	(18.0)	(17.5)	(3.8)

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.